10-K: Cara Therapeutics Prioritizes Neuropathic Pruritus Program After Mixed Results

Cara Therapeutics is focusing its resources on developing oral difelikefalin for neuropathic pruritus associated with notalgia paresthetica (NP) after discontinuing other programs.

Summary

• Cara Therapeutics is a development-stage biopharmaceutical company focused on chronic pruritus.
• The company is prioritizing the development of oral difelikefalin for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP).
• A Phase 2/3 program for oral difelikefalin in NP is underway, with topline results from the dose-finding portion expected in the third quarter of 2024.
• An IV formulation of difelikefalin, KORSUVA, is approved for moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis, but is out-licensed worldwide.
• The company estimates that approximately 650,000 adult patients with NP associated pruritus are under the care of a healthcare provider in the United States.
• The company has sold its future royalties and milestones for Kapruvia and KORSUVA injection to HCR for up to $40 million.
• The company has terminated its Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease, including the ongoing KICK 1 and KICK 2 Phase 3 clinical trials.
• A workforce reduction of approximately 50% was announced to reduce operating expenses and focus on the NP program.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is focusing on a promising program and has secured funding, it has also discontinued other programs, experienced a lack of revenue growth, and reduced its workforce. The overall sentiment is cautiously negative due to the challenges and uncertainties ahead.

Positives

• The company is focusing on a late-stage clinical program with a significant potential market.
• The company has a commercial-stage product, KORSUVA injection, although it is out-licensed.
• The company has secured funding through the sale of future royalties and milestones.
• The company has a clear strategy to focus on NP, which is anchored in the favorable preclinical and clinical profile and benefit of difelikefalin.

Negatives

• The company has terminated its Phase 3 clinical program evaluating oral difelikefalin in pruritus associated with advanced chronic kidney disease.
• The company has experienced a lack of sequential revenue growth for KORSUVA injection since its launch.
• The company expects no meaningful revenue contribution from KORSUVA injection post its TDAPA expiration.
• The company has reduced its global workforce by approximately 50%.

Risks

• The company is substantially dependent on the success of oral difelikefalin for the treatment of NP.
• The company may be unable to successfully execute its strategic prioritization plans, including efforts to reduce costs.
• The company relies on third parties to conduct clinical studies, and those third parties may not perform satisfactorily.
• The company may face delays in the development of its product candidate if manufacturers fail to produce it in required volumes or comply with regulations.
• The company may never achieve profitability.
• The company may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.

Future Outlook

The company expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating plan into 2026.

Management Comments

• The company is focused on chronic pruritus, a condition associated with many diseases across multiple therapeutic areas.
• The company believes its strategy to focus on NP will lead to sustainable, long-term growth.
• The company plans to develop and commercialize oral difelikefalin in chronic pruritus associated with NP on its own in the United States, while exploring partnerships for development and commercialization in geographical territories outside the United States.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. There are a number of companies developing or marketing therapies for different pruritic indications.

Comparison to Industry Standards

• The document mentions several competitors such as Pfizer, AbbVie, Eli Lilly, Amgen, Regeneron, Leo Pharma, Galderma, Chugai, and Incyte, indicating a competitive landscape in the pruritus treatment market.
• The company believes the late-stage nature of its oral difelikefalin clinical program, along with its substantial safety database, would give it an advantage over competitors seeking to develop a competitive product candidate for neuropathic pruritus associated with NP.
• The company expects that its product candidate, if approved, would be priced at a significant premium over generic products, which are often tried off-label for the indication that the company is pursuing.

Management Changes

Related Party Transactions

• CSL Vifor and its affiliates are considered related parties as of December 31, 2023, 2022 and 2021.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's strategic changes and financial performance.
• Employees have been impacted by the workforce reduction.
• Customers may be affected by the discontinuation of certain programs.
• Suppliers may be affected by the company's reduced manufacturing commitments.

Next Steps

• The company will continue the Phase 2/3 program for oral difelikefalin in NP.
• The company expects to release topline results from the dose-finding portion of the Phase 2/3 program in the third quarter of 2024.
• The company expects to release final topline results from the first pivotal study KOURAGE 1 Part B by the end of 2025 with the second pivotal study KOURAGE 2 results in early 2026.

Key Dates

Keywords

difelikefalin, pruritus, notalgia paresthetica, neuropathic pruritus, KORSUVA, Kapruvia, clinical trials, biopharmaceutical, CKD, hemodialysis